Expect Equity LLC Takes $3.56 Million Position in Lantheus Holdings, Inc. $LNTH

Expect Equity LLC bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 32,073 shares of the medical equipment provider’s stock, valued at approximately $3,558,000. Lantheus accounts for about 2.3% of Expect Equity LLC’s investment portfolio, making the stock its 11th biggest position.

A number of other hedge funds have also recently added to or reduced their stakes in LNTH. Reinhart Partners LLC. raised its position in Lantheus by 2.2% in the 2nd quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock valued at $177,437,000 after purchasing an additional 34,501 shares during the last quarter. Versor Investments LP acquired a new stake in Lantheus during the 4th quarter worth $519,000. M&T Bank Corp purchased a new position in Lantheus during the 4th quarter worth $539,000. Epoch Investment Partners Inc. grew its position in Lantheus by 59.4% during the 1st quarter. Epoch Investment Partners Inc. now owns 649,751 shares of the medical equipment provider’s stock worth $49,284,000 after purchasing an additional 242,222 shares during the last quarter. Finally, First Trust Advisors LP increased its stake in Lantheus by 287.6% in the first quarter. First Trust Advisors LP now owns 60,258 shares of the medical equipment provider’s stock valued at $4,571,000 after purchasing an additional 44,713 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on LNTH shares. TD Cowen downgraded Lantheus from a “buy” rating to a “hold” rating and lowered their target price for the company from $110.00 to $102.50 in a research note on Monday, August 3rd. Leerink Partners set a $102.50 price target on Lantheus in a research note on Monday, August 3rd. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. B. Riley Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Monday, August 17th. Finally, CJS Securities cut shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday, August 4th. Four equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $108.11.

Lantheus Trading Up 0.1%

Shares of LNTH stock opened at $100.87 on Wednesday. The business’s fifty day moving average price is $103.92 and its 200 day moving average price is $91.01. Lantheus Holdings, Inc. has a 1-year low of $49.67 and a 1-year high of $111.86. The firm has a market capitalization of $6.58 billion, a PE ratio of 24.36 and a beta of -0.03. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.25. The firm had revenue of $388.18 million during the quarter, compared to analysts’ expectations of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.Lantheus’s revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.57 earnings per share. As a group, sell-side analysts forecast that Lantheus Holdings, Inc. will post 4.48 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.